| Outcome Measures: |
Primary: The primary endpoint of the study is the change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal, The change from baseline of serum C-peptide (pmol/L), Measured at week 26 | Secondary: Change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal, Change from baseline of serum C-peptide area under the curve (AUC) over 2 hours following a mixed meal tolerance test, Measured at week 52|Change from baseline in glycosylated haemoglobin (HbA1c) levels, Change from baseline in HbA1c (%) levels, Measured at weeks 4, 12, 26 and 52|Change from baseline in insulin dosage, Change from baseline in insulin dosage, including total dose and units per kilogram, Measured at week 26 and 52|The frequency and severity of hypoglycemic events, Number and rate of hypoglycemic events including Grade 1, 2 and 3, Measured at week 26 and 52|Drug safety: gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc., Number and rate of gastrointestinal symptoms, rashes, fatigue, bleeding, anemia, infections, cardiovascular events, etc., Measured at week 26 and 52
|
